 Adamantane
"Adamantane" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A tricyclo bridged hydrocarbon.
| Descriptor ID |
D000218
|
| MeSH Number(s) |
D02.455.426.100.050 D02.455.426.392.368.075
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Adamantane".
Below are MeSH descriptors whose meaning is more specific than "Adamantane".
This graph shows the total number of publications written about "Adamantane" by people in UAMS Profiles by year, and whether "Adamantane" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2020 | 3 | 0 | 3 | | 2018 | 1 | 0 | 1 | | 2017 | 1 | 1 | 2 | | 2015 | 0 | 1 | 1 | | 2013 | 1 | 0 | 1 | | 2011 | 0 | 1 | 1 | | 2009 | 2 | 0 | 2 | | 2006 | 1 | 0 | 1 | | 2005 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Adamantane" by people in Profiles over the past ten years.
-
Pinson AO, Pouncey DL, Schleiff MA, Fantegrossi WE, Prather PL, Radominska-Pandya A, Boysen G, Miller GP. Significance of Competing Metabolic Pathways for 5F-APINACA Based on Quantitative Kinetics. Molecules. 2020 Oct 20; 25(20).
-
Pinson A, Yarbrough AL, Bush JM, Cabanlong CV, Shoeib A, Jackson BK, Fukuda S, Gogoi J, Fantegrossi WE, McCain K, Prather PL, Fujiwara R, Radominska-Pandya A. Metabolism, CB1 cannabinoid receptor binding and in vivo activity of synthetic cannabinoid 5F-AKB48: Implications for toxicity. Pharmacol Biochem Behav. 2020 08; 195:172949.
-
Jones S, Yarbrough AL, Fantegrossi WE, Prather PL, Bush JM, Radominska-Pandya A, Fujiwara R. Identifying cytochrome P450s involved in oxidative metabolism of synthetic cannabinoid N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide (STS-135). Pharmacol Res Perspect. 2020 02; 8(1):e00561.
-
Dai L, Smith CD, Foroozesh M, Miele L, Qin Z. The sphingosine kinase 2 inhibitor ABC294640 displays anti-non-small cell lung cancer activities in vitro and in vivo. Int J Cancer. 2018 05 15; 142(10):2153-2162.
-
Dai L, Bai A, Smith CD, Rodriguez PC, Yu F, Qin Z. ABC294640, A Novel Sphingosine Kinase 2 Inhibitor, Induces Oncogenic Virus-Infected Cell Autophagic Death and Represses Tumor Growth. Mol Cancer Ther. 2017 Dec; 16(12):2724-2734.
-
Tai S, Fantegrossi WE. Pharmacological and Toxicological Effects of Synthetic Cannabinoids and Their Metabolites. Curr Top Behav Neurosci. 2017; 32:249-262.
-
Asakura M, Fukami T, Nakajima M, Fujii H, Atsuda K, Itoh T, Fujiwara R. Hepatic Dipeptidyl Peptidase-4 Controls Pharmacokinetics of Vildagliptin In Vivo. Drug Metab Dispos. 2017 02; 45(2):237-245.
-
Asakura M, Karaki F, Fujii H, Atsuda K, Itoh T, Fujiwara R. Vildagliptin and its metabolite M20.7 induce the expression of S100A8 and S100A9 in human hepatoma HepG2 and leukemia HL-60 cells. Sci Rep. 2016 10 19; 6:35633.
-
Yamashita Y, Asakura M, Mitsugi R, Fujii H, Nagai K, Atsuda K, Itoh T, Fujiwara R. MicroRNA expression in the vildagliptin-treated two- and three-dimensional HepG2 cells. Drug Metab Pharmacokinet. 2016 Jun; 31(3):201-9.
-
Dai L, Trillo-Tinoco J, Bai A, Chen Y, Bielawski J, Del Valle L, Smith CD, Ochoa AC, Qin Z, Parsons C. Ceramides promote apoptosis for virus-infected lymphoma cells through induction of ceramide synthases and viral lytic gene expression. Oncotarget. 2015 Sep 15; 6(27):24246-60.
-
Asakura M, Fujii H, Atsuda K, Itoh T, Fujiwara R. Dipeptidyl peptidase-4 greatly contributes to the hydrolysis of vildagliptin in human liver. Drug Metab Dispos. 2015 Apr; 43(4):477-84.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|